Viking Therapeutics (VKTX) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Viking Therapeutics (VKTX) over the past year, losing 1.3% versus a loss of 27.7%. Over five years, VKTX leads with a +360.4% price change compared with +63.7% for VRDN. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.16 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VKTX | VRDN |
|---|---|---|
| Share price | $24.77 | $29.96 |
| Market cap | $3.16B | $3.40B |
| 1-day change | -4.14% | -4.71% |
| YTD return | -29.59% | -3.73% |
| 1-year return | -27.70% | -1.25% |
| 5-year return | +360.41% | +63.72% |
| EPS (TTM) | $-5.42 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-359.64M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $43.10 | $34.29 |
| 52-week low | $23.82 | $13.18 |
| Distance from 52-week high | -42.53% | -12.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +284.82% | +42.72% |
| Average volume | 5.31M | 2.14M |
| Shares outstanding | 127.52M | 113.56M |
| Employees | 74 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRDN has outperformed VKTX by 26.4 percentage points over the past year.
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
VKTX vs VRDN FAQ
Which is bigger, Viking Therapeutics or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.16B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, VKTX or VRDN?
VRDN returned -1.25% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Viking Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.